Skip to main content

Table 3 Specific treatment and prognosis of 15 selected ROGDI-related KTS patients

From: Perampanel effectiveness in treating ROGDI-related Kohlschütter-Tönz syndrome: first reported case in China and literature review

Pt

ASMs

ACTH

VNS

KD

Prognosis

Controlling drug

Controlling age

Num

Specific drugs (age)

6

3

phenytoin, primidone, nitrazepam

-

-

-

LE

-

-

12

3

PHB, CBZ

VPA

-

-

-

LE

-

-

13

2

PHB, CBZ

-

-

-

LE

-

-

14

4

PHB, CBZ, VPA, CLB

-

-

-

E

VPA, CLB

-

15

3

VPA, CBZ, CLB

-

-

-

E

CLB

-

16

2

PHB, VGB

-

-

-

E

PHB, VGB

-

17

1

LEV

-

-

-

LE

-

-

18

1

LEV

-

-

-

LE

-

-

38

5

CBZ, TPM, CZP, VGB, PHB

-

-

 + 

LE

-

-

39

2

Phenytoin, CLB

-

-

-

E

Phenytoin, CLB

-

40

2

PHB, LEV

-

-

-

E

PHB, LEV

4y

41

2

PHB, LEV

-

-

-

LE

-

-

42

3

CLB, ethosuximide, primidone

-

-

-

LE

-

-

43

2

VBZ, PMP

-

 + 

 + 

E

PMP

-

44

3

VPA, LEV, PMP

-

-

-

E

PMP

-

  1. ASMs anti-seizure medications, Num number of types, ACTH adrenocorticotropic hormone, LE less effective, seizure frequency reduction less than 50%/ineffective/aggravated, E effective, seizure frequency reduction over 50%/seizure free, PHB phenobarbital, KD ketogenic diet, CBZ carbamazepine, VPA valproate, CLB clobacam, VGB vigabatrin, LEV levetiracetam, TPM topiramate, CZP clonazepam
Back to article page

BMC Medical Genomics

ISSN: 1755-8794

Contact us